News & Updates

Selpercatinib, a highly selective and potent RET inhibitor, trumped two multikinase inhibitors (MKIs) – cabozantinib and vandetanib – for the treatment of advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC) in the first-line (1L) setting, according to the interim analysis results of the phase III LIBRETTO-531 trial.

Several factors are directly associated with either an increase or a decrease of pharmacokinetic parameters of doxorubicin, reports a recent study.

Local transdermal therapy with 4-hydroxytamoxifen appears to be less effective than full-dose oral tamoxifen in terms of suppressing proliferation in ductal carcinoma in situ lesions for breast cancer prevention, according to a phase II study.

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).